Literature DB >> 24528911

Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.

Jenny E Murase1, Misha M Heller2, Daniel C Butler3.   

Abstract

Dermatologists are frequently faced with questions about the safety of commonly prescribed topical and systemic medications during pregnancy and lactation from women of childbearing age who are pregnant, considering pregnancy, or breastfeeding. Safety data, particularly regarding medications that are unique to dermatology, can be difficult to locate and are not consolidated in a single reference guide for clinicians. Parts I and II of this continuing medical education article provide a capsule summary of key points for the most commonly prescribed dermatologic medications to facilitate patient medication risk counseling in pregnancy. A summary table details safety classification data for 3 primary international classification systems: the US Food and Drug Administration, the Swedish Catalogue of Approved Drugs, and the Australian Drug Evaluation Committee. In addition, this table includes an alternative pregnancy classification system developed by a consortium of active members of teratology societies in the US and Europe detailed in Drugs during Pregnancy and Lactation: Treatment Options and Risk Assessment and a safety classification system developed for breastfeeding mothers detailed in Medications and Mother's Milk.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  acne; antibiotic; antifungal; antihistamines; antiviral; atopic dermatitis; biologics; breast milk; breastfeeding; corticosteroid; cosmetics; fetus; gestation; lactation; medication safety; nursing; phototherapy; pregnancy; psoriasis; surgery; trimester

Mesh:

Substances:

Year:  2014        PMID: 24528911     DOI: 10.1016/j.jaad.2013.09.010

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  28 in total

Review 1.  [Specific dermatoses of pregnancy].

Authors:  C M Ambros-Rudolph; M Sticherling
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

Review 2.  [Dermatological topical and systemic therapy during pregnancy].

Authors:  S Grunewald; P Staubach
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

3.  Lack of pregnancy warnings on over-the-counter dermatologic products containing potentially harmful hydroquinone.

Authors:  L L Bio; J J Cies
Journal:  J Perinatol       Date:  2017-03-30       Impact factor: 2.521

4.  Proceeding report of the third symposium on Hidradenitis Suppurativa advances (SHSA) 2018.

Authors:  Claudia J Posso-De Los Rios; Akua Sarfo; Mondana Ghias; Raed Alhusayen; Iltefat Hamzavi; Michelle A Lowes; Afsaneh Alavi
Journal:  Exp Dermatol       Date:  2019-04-29       Impact factor: 3.960

Review 5.  [Prurigo. Clinical definition and classification].

Authors:  F Schedel; C Schürmann; D Metze; S Ständer
Journal:  Hautarzt       Date:  2014-08       Impact factor: 0.751

Review 6.  Current Management of Pediatric Vitiligo.

Authors:  Freya Van Driessche; Nanette Silverberg
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

Review 7.  Skin Changes and Safety Profile of Topical Products During Pregnancy.

Authors:  Imam Budi Putra; Nelva Karmila Jusuf; Nani Kumala Dewi
Journal:  J Clin Aesthet Dermatol       Date:  2022-02

8.  TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors.

Authors:  Julie J Hong; Edward K Hadeler; Megan L Mosca; Nicholas D Brownstone; Tina Bhutani; Wilson J Liao
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2022-01-12

9.  A case of minimal change disease during pregnancy - benefits of early diagnosis and use of corticosteroids.

Authors:  Priyanka S Sagar; Eddy Fischer; Muralikrishna Gangadharan Komala; Bhadran Bose
Journal:  Obstet Med       Date:  2021-02-09

Review 10.  Gestational pemphigoid.

Authors:  Laura Huilaja; Kaarin Mäkikallio; Kaisa Tasanen
Journal:  Orphanet J Rare Dis       Date:  2014-09-02       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.